Forum Financial Management LP Boosts Position in Sanofi $SNY

Forum Financial Management LP boosted its holdings in Sanofi (NASDAQ:SNY) by 21.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 69,279 shares of the company’s stock after purchasing an additional 12,250 shares during the quarter. Forum Financial Management LP’s holdings in Sanofi were worth $3,270,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raymond James Financial Inc. lifted its position in shares of Sanofi by 81.3% during the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after buying an additional 2,635,867 shares during the last quarter. Regal Partners Ltd raised its stake in Sanofi by 102.3% during the 2nd quarter. Regal Partners Ltd now owns 1,548,204 shares of the company’s stock worth $74,794,000 after acquiring an additional 782,838 shares in the last quarter. NewEdge Advisors LLC lifted its position in Sanofi by 1,853.1% in the second quarter. NewEdge Advisors LLC now owns 731,208 shares of the company’s stock valued at $35,325,000 after acquiring an additional 693,770 shares during the last quarter. American Century Companies Inc. boosted its stake in Sanofi by 29.3% in the second quarter. American Century Companies Inc. now owns 1,959,185 shares of the company’s stock valued at $94,648,000 after acquiring an additional 443,941 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Sanofi by 9.9% during the second quarter. Franklin Resources Inc. now owns 4,274,410 shares of the company’s stock worth $206,497,000 after purchasing an additional 384,902 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on SNY shares. Guggenheim downgraded Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. Barclays cut Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Monday, December 29th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $62.67.

Sanofi Price Performance

Sanofi stock opened at $49.03 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.30. The business has a 50 day simple moving average of $49.21 and a 200-day simple moving average of $48.87. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The stock has a market capitalization of $119.58 billion, a PE ratio of 11.48, a price-to-earnings-growth ratio of 1.22 and a beta of 0.45.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 24th. The company reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $1.31. The firm had revenue of $15.46 billion for the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. Sanofi’s quarterly revenue was down 7.5% on a year-over-year basis. During the same period last year, the firm posted $2.25 EPS. Equities analysts predict that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.